Key regions: Brazil, India, Australia, United States, United Kingdom
The demand for antiviral drugs in the Baltics region has been on the rise in recent years.
Customer preferences: The increase in demand for antiviral drugs in the Baltics region can be attributed to the growing awareness among consumers about the benefits of these drugs in treating viral infections. Customers in the region are increasingly seeking antiviral drugs that are effective against a wide range of viral infections and have minimal side effects.
Trends in the market: One of the major trends in the antiviral drugs market in the Baltics region is the increasing focus on developing new and innovative drugs to treat viral infections. Pharmaceutical companies are investing heavily in research and development to come up with new drugs that are more effective and have fewer side effects. Another trend in the market is the growing popularity of combination therapies, which involve the use of two or more antiviral drugs to treat viral infections.
Local special circumstances: The Baltics region comprises three countries: Estonia, Latvia, and Lithuania. Each of these countries has its own unique healthcare system and regulatory environment. In Estonia, for example, the government has introduced several measures to promote the use of generic drugs, which has led to increased competition in the market and lower prices for consumers. In Latvia, the government has implemented a centralized procurement system for drugs, which has helped to reduce the cost of healthcare for patients.
Underlying macroeconomic factors: The growing demand for antiviral drugs in the Baltics region can be attributed to several macroeconomic factors. One of the key factors is the increasing prevalence of viral infections, such as influenza and hepatitis, in the region. Another factor is the growing aging population, which is more susceptible to viral infections. Additionally, the increasing disposable income of consumers in the region has made it possible for them to afford more expensive drugs, including antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
